As the use of glucagon-like peptide-1 receptor agonists (GLP-1) medications explodes, retail insurance agents need to be aware of the emerging exposures associated with them
Consequently, companies such as Novo Nordisk and Eli Lilly are investing heavily in next-generation formulations, including oral small-molecule GLP-1 receptor agonists such as orforglipron, which aim to expand patient accessibility and therapeutic scope The demand for GLP-1 drugs that address a wider array of metabolic conditions is growing rapidly across global markets, as patients and healthcare providers increasingly seek holistic and effective long-term treatment options for obesity and its comorbidities GLP-1 Receptor Agonists Obesity Drugs Market Dynamics Driver Surging Demand Due to Rising Obesity Prevalence and Enhanced Clinical Outcomes The global surge in obesity rates and associated comorbidities such as type 2 diabetes and cardiovascular diseases is significantly driving demand for GLP-1 receptor agonist drugs as effective medical weight loss therapies For instance, in May 2024, Novo Nordisk announced a USD 4.1 billion expansion in its U.S
This surgery is successful for some but not all patients
Empagliflozin Side Effects, Risk, and Complications Empagliflozin, while a powerful tool in managing type 2 diabetes and offering benefits beyond glycemic control, has its share of potential side effects and risks as well
,aspect=ignore)
